We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

70 hedge funds and large institutions have $105M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

747% more call options, than puts

Call options by funds: $144K | Put options by funds: $17K

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $112M → $105M (-$6.72M)

7% less funds holding

Funds holding: 75 → 70 (-5)

29% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 17

Holders
70
Holders Change
-5
Holders Change %
-6.67%
% of All Funds
1.01%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
19
Reduced
11
Closed
17
Calls
$144K
Puts
$17K
Net Calls
+$127K
Net Calls Change
-$32K

Top Buyers

Rank Fund Capital Flow
1
EAM
Exome Asset Management
New York
+$836K
2
ECM
ExodusPoint Capital Management
New York
+$571K
3
UOC
UBS O'Connor
Illinois
+$542K
4
OM
Opaleye Management
Massachusetts
+$409K
5
PCM
Prelude Capital Management
New York
+$212K

Top Sellers

Rank Fund Capital Flow
1
DMKJ
David M. Knott Jr
-$1.25M
2
Millennium Management
Millennium Management
New York
-$1.04M
3
Goldman Sachs
Goldman Sachs
New York
-$968K
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$810K
5
Jane Street
Jane Street
New York
-$701K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCLSI
1
Bain Capital Life Sciences Investors
Massachusetts
$14.2M – – –
AG
2
Artal Group
Luxembourg
$12.9M – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$10.7M – – –
SB
4
Samsara BioCapital
California
$9.22M – – –
APM
5
Avidity Partners Management
Texas
$8.64M – – –
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$7.59M – – –
FP
7
Flagship Pioneering
Massachusetts
$6.68M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$5M +$211K +40,171 +4%
OM
9
Opaleye Management
Massachusetts
$4.47M +$409K +77,898 +10%
DTC
10
Deep Track Capital
Connecticut
$4.27M – – –
KCM
11
Kennedy Capital Management
Missouri
$2.21M +$119K +22,622 +6%
BOCH
12
Blue Owl Capital Holdings
New York
$1.76M – – –
Walleye Capital
13
Walleye Capital
New York
$1.47M +$4.56K +867 +0.3%
UOC
14
UBS O'Connor
Illinois
$1.44M +$542K +103,103 +59%
ECM
15
ExodusPoint Capital Management
New York
$1.36M +$571K +108,702 +70%
Goldman Sachs
16
Goldman Sachs
New York
$1.35M -$968K -184,218 -41%
BlackRock
17
BlackRock
New York
$1.34M +$11.3K +2,148 +0.8%
OFM
18
Omega Fund Management
Massachusetts
$1.3M – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.17M +$30.8K +5,865 +3%
Marshall Wace
20
Marshall Wace
United Kingdom
$828K +$4.24K +806 +0.5%
EAM
21
Exome Asset Management
New York
$821K +$836K +159,175 New
DCM
22
DAFNA Capital Management
California
$701K – – –
Renaissance Technologies
23
Renaissance Technologies
New York
$606K -$12.6K -2,400 -2%
PA
24
Perceptive Advisors
New York
$602K – – –
LPL Financial
25
LPL Financial
California
$395K +$2.63K +500 +0.7%
1
2 3 4

SYRS Hedge Fund Activity: Q2 2024 in Review

70 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2024, worth a combined $105M — down 6% from $112M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of SYRS and 12 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 19 added.

The largest buyer was Exome Asset Management, opening a new position worth an estimated $836K. The largest seller was David M. Knott Jr, exiting entirely with an estimated $1.25M sold.

  • 70 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2024, down from 75 in Q1 2024.
  • Funds reported $105M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 6% quarter-over-quarter.
  • 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 17 closed out, a net change of -5 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2024 was Exome Asset Management, an estimated $836K added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was David M. Knott Jr, an estimated $1.25M sold.

Based on aggregated 13F filings for Q2 2024.